ClinicalTrials.gg
RecruitingNCT07696715TIME-NLUpdated Aug 13, 2026

Timing of Immunotherapy in Melanoma

An interventional study of Timing of first administration (early morning) and Timing of immunotherapy (afternoon) in Melanoma, sponsored by Radboud University Medical Center. Recruiting at 5 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Radboud University Medical Center · Not applicable, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Melanoma by Radboud University Medical Center — 2 open to participants now, 2 under way, none of them phase 3. Melanoma · Radboud University Medical Center.

Planned enrollment
Largest of 11
170 · median 40
Started
2026
with 1 other
No phase
Only one
of the 11
Registered
11th of 11
by date

Among the 11 studies in Melanoma by Radboud University Medical Center, this one has the largest planned enrollment, is one of 2 that started in 2026, is the only one with no phase, and was the 11th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

2 of the 11 studies in Melanoma by Radboud University Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Melanoma by Radboud University Medical Center, or all of them as a file.
02

Study summary

The TIME-NL trial is a multicenter, randomized, open-label clinical trial in the Netherlands to assess the effect of the timing of the first administration of standard-of-care intravenous combination immunotherapy (early morning versus afternoon) in patients with metastatic melanoma. Patients will be randomized 1:1 to start standard-of-care ICI administration either before 10am (early morning arm; arm A) or after 1pm (afternoon arm; arm B). Patients will be stratified according to performance status and study center. The randomized clinical trial will be part of a hybrid design in which data from the randomized clinical trial will be combined with observational data.

03

Conditions studied

  • Melanoma

Browse trials for

Keywords

  • melanoma
  • chronoimmunotherapy
  • timing
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed cutaneous melanoma, classified as irresectable (stage III) or (stage IV) disease.
  • At least 18 years of age.
  • World Health Organization (WHO) Performance Status 0-1.
  • according to 1.1.
  • Starting treatment with standard-of-care combination immunotherapy (ipilimumab+nivolumab) as treatment.
  • Signed form

Exclusion criteria

Exclusion Criteria:

  • Uveal or mucosal melanoma (unknown primary melanoma is allowed).
  • Use of systemic medications. Inhaled or topical are permitted.
  • Use of adrenal replacement medications, e.g. hydrocortisone.
  • Use of melatonin agonists.
  • Prior systemic therapy for irresectable/ melanoma (prior T-VEC is allowed)
  • Prior systemic therapy for resectable melanoma in the last 6 months ( and adjuvant treatment is allowed if at least 6 months ago).
  • Use of drugs.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
170 participants (estimated)

Study arms

  • Active comparator
    A: early morning immunotherapy

    Standard-of-care immune checkpoint inhibition with ipilimumab + nivolumab with the first administration starting before 10am

    Other: Timing of first administration (early morning)

  • Active comparator
    B: afternoon immunotherapy

    Standard-of-care immune checkpoint inhibition with ipilimumab + nivolumab with the first administration starting after 1pm

    Other: Timing of immunotherapy (afternoon)

Interventions

  • OtherTiming of first administration (early morning)

    The timing of the first administration of combination immunotherapy starting before 10am

  • OtherTiming of immunotherapy (afternoon)

    The timing of the first administration of combination immunotherapy starting after 1pm

This study also gives NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., IpilimumabStudies of IpilimumabIpilimumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Best overall response rate

    Best overall response rate (radiological complete or partial response according to RECIST 1.1)

    Time frame: from enrollment to 1year

07

Study locations

1 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared due to ethical and privacy considerations.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Sep 2029, 37 months after the start.

Of 220 non-industry interventional studies with no phase under Melanoma, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 37 months is close to that.

Counting every sponsor, half of 228 studies reached it within 38 months; a quarter within 20 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2026
First posted
Jul 10, 2026
StartActual
Aug 10, 2026
Primary completionEst.
Sep 30, 2029
CompletionEst.
Sep 30, 2033
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07696715
Responsible party
Sponsor
First posted
Jul 10, 2026
Start date
Aug 10, 2026
Primary completion
Sep 30, 2029 (estimated)
Completion
Sep 30, 2033 (estimated)
Last update
Aug 13, 2026

Study contacts

Kalijn Bol, MD/PhD
Contact
kalijn.bol@radboudumc.nl
+31243618800
Mirte Meijerink
Contact
studies.onco@radboudumc.nl

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Ipilimumab

Start the discussion